In the acute post-myocardial infarction setting, SGLT2 inhibitor treatment has been associated with smaller infarct size, lower in-hospital arrhythmias and in-hospital cardiovascular mortality, and reduced levels of NT-proBNP suggesting acute effects.17, 18, 19 Intensive glucose-lowering therapy has not clearly correlated with lower rates of cardiovascular events or lowered mortality, and the cardioprotective effect of SGLT2 inhibitors does not appear to be related to the glucose-lowering effect.20 This evidence concerns the gene SLC5A2 and Arrhythmia.